麻疹、腮腺炎、德国麻疹疫苗市场－全球产业规模、份额、趋势、机会和预测，按类型、目标族群、配销通路、地区和竞争细分，2020-2030 年

2024 年全球麻疹、腮腺炎和德国麻疹 (MMR) 疫苗市值为 18.7 亿美元，预计到 2030 年将达到 30.4 亿美元，预测期内复合年增长率为 8.42%。作为一项基本公共卫生措施，免疫接种的需求不断增长，推动了市场的成长。在世界卫生组织和联合国儿童基金会等国际机构的支持下，MMR疫苗被纳入国家免疫接种计划，并在高收入国家和低收入国家广泛采用。麻疹疫情反覆爆发，特别是在医疗资源匮乏的人群中，凸显了大规模疫苗接种运动的必要性。加强医疗保健基础设施、公私合作伙伴关係以及改善分销物流正在进一步提高疫苗的可及性和覆盖率。

疫苗接种方法的创新，包括耐热和无针製剂，也正在推动成长，特别是在资源受限的环境中。将 MMR 与其他儿科疫苗结合成单剂量形式的趋势正在简化免疫接种计划并提高依从性。与数位健康系统的整合有助于追踪疫苗接种覆盖率和后续情况，提高专案效率。

关键市场驱动因素

加强政府免疫接种计划

主要市场挑战

疫苗犹豫和错误讯息

主要市场趋势

将 MMR 疫苗纳入普遍免疫计划

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球麻疹、腮腺炎、德国麻疹疫苗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依类型（单价、三价（MMR联合）、四价）
  • 依目标族群（婴儿和儿童（9个月至12岁）、成人）
  • 按配销通路（医院和医疗机构、疫苗中心和公共卫生诊所、儿科和私人医疗诊所）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美麻疹、腮腺炎、德国麻疹疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲麻疹、腮腺炎、德国麻疹疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区麻疹、腮腺炎、德国麻疹疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美洲麻疹、腮腺炎、德国麻疹疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲麻疹、腮腺炎、德国麻疹疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Serum Institute of India Pvt. Ltd.
• Panacea Biotec Ltd.
• Takeda Pharmaceutical Company Limited
• Sinovac Biotech Ltd.
• Biological E. Limited
• Emergent BioSolutions Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

The Global Measles, Mumps, and Rubella (MMR) Vaccine Market was valued at USD 1.87 billion in 2024 and is projected to reach USD 3.04 billion by 2030, growing at a CAGR of 8.42% during the forecast period. Market growth is being fueled by increasing demand for immunization as a fundamental public health measure. The inclusion of MMR vaccines in national immunization schedules, bolstered by support from international agencies such as WHO and UNICEF, has led to widespread adoption in both high- and low-income countries. Recurring outbreaks of measles, especially in underserved populations, highlight the need for large-scale vaccination campaigns. Strengthening healthcare infrastructure, public-private partnerships, and improved distribution logistics are further enhancing vaccine access and coverage.

Innovation in vaccine delivery methods, including thermostable and needle-free formulations, is also driving growth, particularly in resource-constrained settings. The trend of combining MMR with other pediatric vaccines into a single-dose format is simplifying immunization schedules and improving adherence. Integration with digital health systems is aiding in tracking vaccination coverage and follow-ups, enhancing program efficiency.

Key Market Drivers

Increasing Government Immunization Initiatives

Government-led immunization initiatives have become a pivotal factor driving the global MMR vaccine market. Countries worldwide are prioritizing vaccine-preventable disease control by integrating MMR into routine childhood immunization programs, often at no cost. Increased funding, improved logistics, and targeted rural outreach are elevating vaccine coverage. Supported by organizations such as WHO, UNICEF, and Gavi, these initiatives are reducing disease incidence and mortality, particularly in low-income nations.

Despite such efforts, global immunization coverage still falls short of WHO's 95% target needed for measles elimination. In 2023, only 83% of children globally received the first measles vaccine dose, while just 74% received the second. Alarmingly, over 22 million children missed their first dose. These figures underline the urgency for governments to scale up immunization efforts through enhanced policies, monitoring, and education, reinforcing sustained demand for MMR vaccines.

Key Market Challenges

Vaccine Hesitancy and Misinformation

Vaccine hesitancy, driven by misinformation and distrust, remains a substantial barrier to broader adoption of MMR vaccines. Persistent myths, such as a link between the MMR vaccine and autism, continue to undermine public confidence despite being scientifically disproven. The proliferation of false information via social media and other platforms exacerbates hesitancy, particularly in communities with limited access to reliable healthcare education.

These attitudes delay or reduce vaccine uptake, leading to disease resurgence and undermining public health goals. Overcoming this issue requires coordinated efforts involving community leaders, healthcare providers, and policymakers to promote accurate information and build trust. Tailored education campaigns and transparent communication strategies will be key to addressing misinformation and improving vaccine acceptance across regions.

Key Market Trends

Integration of MMR Vaccines into Universal Immunization Programs

The increasing integration of MMR vaccines into universal immunization programs is a notable trend supporting market expansion. Governments, with backing from global health bodies, are embedding MMR vaccination within broader public health strategies to improve childhood immunization coverage. These efforts are essential in achieving herd immunity and controlling disease outbreaks.

According to WHO, global measles vaccine coverage remains insufficient, with only 83% of children receiving the first dose and 74% the second in 2023. Nearly 35 million children lacked full protection against measles. These gaps emphasize the need for inclusive immunization strategies. As countries intensify efforts to close these coverage gaps, the demand for reliable MMR vaccines is expected to grow significantly.

Key Market Players

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Serum Institute of India Pvt. Ltd.
• Panacea Biotec Ltd.
• Takeda Pharmaceutical Company Limited
• Sinovac Biotech Ltd.
• Biological E. Limited
• Emergent BioSolutions Inc.

Report Scope

In this report, the Global Measles, Mumps, Rubella Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Measles, Mumps, Rubella Vaccine Market, By Type:

• Monovalent
• Trivalent (combined MMR)
• Tetravalent

Measles, Mumps, Rubella Vaccine Market, By Targeted Population:

• Infants and Children (9 months to 12 years)
• Adults

Measles, Mumps, Rubella Vaccine Market, By Distribution Channel:

• Hospitals and Healthcare Institutions
• Vaccine Centers and Public Health Clinics
• Pediatric and Private Healthcare Clinics

Measles, Mumps, Rubella Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Measles, Mumps, Rubella Vaccine Market.

Available Customizations

Global Measles, Mumps, Rubella Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Measles, Mumps, Rubella Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Monovalent, Trivalent (combined MMR), Tetravalent)
  • 5.2.2. By Targeted Population (Infants and children (9 months to 12), Adults)
  • 5.2.3. By Distribution Channel (Hospitals and Healthcare Institutions, Vaccine Centers and Public Health Clinics, Pediatric and Private Healthcare Clinics)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Measles, Mumps, Rubella Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Targeted Population
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Targeted Population
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Targeted Population
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Targeted Population
      • 6.3.3.2.3. By Distribution Channel

7. Europe Measles, Mumps, Rubella Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Targeted Population
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Targeted Population
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Targeted Population
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Targeted Population
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Targeted Population
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Targeted Population
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Measles, Mumps, Rubella Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Targeted Population
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Targeted Population
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Targeted Population
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Targeted Population
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Targeted Population
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Targeted Population
      • 8.3.5.2.3. By Distribution Channel

9. South America Measles, Mumps, Rubella Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Targeted Population
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Targeted Population
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Targeted Population
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Targeted Population
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Measles, Mumps, Rubella Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Targeted Population
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Targeted Population
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Targeted Population
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Targeted Population
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Merck & Co., Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. GlaxoSmithKline plc
• 14.3. Pfizer Inc.
• 14.4. Novartis AG
• 14.5. Serum Institute of India Pvt. Ltd.
• 14.6. Panacea Biotec Ltd.
• 14.7. Takeda Pharmaceutical Company Limited
• 14.8. Sinovac Biotech Ltd.
• 14.9. Biological E. Limited
• 14.10. Emergent BioSolutions Inc.

15. Strategic Recommendations

16. About Us & Disclaimer